The biological and immune-protective properties of
surfactant-derived
phospholipids and
phospholipid subfractions in the context of neonatal inflammatory
lung disease are widely unknown. Using a porcine neonatal triple-hit
acute respiratory distress syndrome (ARDS) model (repeated airway lavage, overventilation, and LPS instillation into airways), we assessed whether the supplementation of
surfactant (S;
poractant alfa) with
inositol derivatives [
inositol 1,2,6-trisphosphate (IP3) or
phosphatidylinositol 3,5-bisphosphate (PIP2)] or
phosphatidylglycerol subfractions [16:0/18:1-palmitoyloleoyl-
phosphatidylglycerol (POPG) or 18:1/18:1-dioleoyl-
phosphatidylglycerol (
DOPG)] would result in improved clinical parameters and sought to characterize changes in key inflammatory pathways behind these improvements. Within 72 h of
mechanical ventilation, the oxygenation index (S+IP3, S+PIP2, and S+POPG), the ventilation efficiency index (S+IP3 and S+POPG), the compliance (S+IP3 and S+POPG) and resistance (S+POPG) of the respiratory system, and the extravascular lung water index (S+IP3 and S+POPG) significantly improved compared with S treatment alone. The
inositol derivatives (mainly S+IP3) exerted their actions by suppressing
acid sphingomyelinase activity and dependent
ceramide production, linked with the suppression of the
inflammasome nucleotide-binding domain,
leucine-rich repeat-containing protein-3 (NLRP3)-apoptosis-associated speck-like
protein containing a caspase recruitment domain (ASC)-caspase-1 complex, and the profibrotic response represented by the
cytokines transforming growth factor-β1 and IFN-γ,
matrix metalloproteinase (
MMP)-1/8, and
elastin. In addition, IκB
kinase activity was significantly reduced. S+POPG and S+DOPG treatment inhibited polymorphonuclear leukocyte activity (
MMP-8 and
myeloperoxidase) and the production of
interleukin-6, maintained alveolar-capillary barrier functions, and reduced alveolar epithelial cell apoptosis, all of which resulted in reduced
pulmonary edema. S+DOPG also limited the profibrotic response. We conclude that highly concentrated
inositol derivatives and
phosphatidylglycerol subfractions in
surfactant preparations mitigate key inflammatory pathways in inflammatory
lung disease and that their clinical application may be of interest for future treatment of the acute exudative phase of neonatal ARDS.